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Synergism between two antibiotics is usually tested by a checkerboard titration technique, or by time-kill
methods. Both methods have the disadvantage that synergism is determined at constant concentrations of the
antibiotics, which do not reflect reality in vivo. In the present study we determined whether synergism between
tobramycin and ceftazidime can be found at declining concentrations below the MIC, and whether change in
dosing sequence of the antibiotics would result in differences in killing. Three monotherapy and six combina-
tion therapy schedules were tested in an in vitro pharmacokinetic model, using a Pseudomonas aeruginosa
resistant to both antibiotics. During all q8h dosing schedules the peak concentration (Cmax) was adjusted to
the MIC for the strain of both antibiotics. During all monotherapy regimens bacterial growth was present,
while all six combination therapy schedules showed significant killing. At t 5 24 h there were no differences
between all combination therapy schedules, but at t 5 8 h the two combination therapy schedules with
administration of tobramycin once daily showed a significantly faster killing. By using the area under the
killing curve (AUKC) as a parameter for synergistic killing, simultaneous combination therapy starting with
tobramycin once daily was significantly better than all other regimens. We conclude that there is synergism
between tobramycin and ceftazidime at declining antibiotic concentrations below the MIC, resulting in a
pronounced killing of a resistant Pseudomonas strain. Infections due to resistant Pseudomonas strains could
possibly be treated by a synergistic combination of these drugs.
Infections caused by Pseudomonas aeruginosa continue to
pose a therapeutic dilemma because of the high rates of mor-
bidity and mortality, and the possibility of drug resistance de-
veloping during therapy. Especially in patients with cystic fi-
brosis emergence of antibiotic-resistant Pseudomonas
aeruginosa strains is observed and it is associated with the
frequent requirement for antibiotic therapy in these patients
(22). One way to overcome this problem is to use combination
therapy. Both in animal models (14, 15, 19, 27) and in clinical
therapy (16, 17) treatment with a combination of an aminogly-
coside with a b-lactam has shown increased efficacy. Such com-
bination therapy is generally used to increase bactericidal ac-
tivity and/or the rate of killing in vivo, and to prevent the
emergence of drug resistance. Combination therapy is also
used to broaden the antimicrobial spectrum in critically ill
patients while awaiting a bacteriologic diagnosis or because
patients have suspected or proven polymicrobial infections (8).
The increased clinical response to combination therapy is usu-
ally explained to be due to synergism between the antibiotics
used. Synergism of a combination of antibiotics can be ex-
pressed as fractional inhibitory concentration indices (FICi)
derived from a checkerboard titration (2, 6, 11, 26). Another
way to detect synergism is by performing time kill curve studies
(11, 28). However, these methods only use constant concen-
trations of the antibiotics, which do not take dynamically
changing concentrations into account, as seen in humans. It
has been suggested that synergism should be investigated using
time kill experiments determined in in vitro models that can
simulate human pharmacokinetics (1, 3, 31).
The purpose of the present study was twofold: (i) to deter-
mine whether synergism was present between tobramycin and
ceftazidime against a strain of Pseudomonas aeruginosa that is
resistant to both antibiotics, during declining antibiotic con-
centrations, thus resulting in killing at concentrations below
the MIC, and (ii) whether different dosing regimens of the
antibiotics result in differences in the rate of killing.
MATERIALS AND METHODS
Bacterial strain and media. The strain used for this experiment was Pseudo-
monas aeruginosa CF 133, a non-mucoid strain, isolated from sputum of a cystic
fibrosis patient. The MIC was 16 mg/liter for tobramycin and 64 mg/liter for
ceftazidime, as determined by standard broth macrodilution method in supple-
mented Mueller-Hinton broth and by agar dilution method on ISO sensitest agar
(ISO; Oxoid, Basingstoke, Hampshire, England) (24), using P. aeruginosa ATCC
27853 as a test strain. The mechanism of resistance for aminoglycosides was
partly determined by identification of the aminoglycoside-modifying enzymes as
described by Van de Klundert et al. (30). The mechanism of resistance for
b-lactam antibiotics was determined by semi-quantitative susceptibility testing,
substrate analysis and iso-electric focusing of the extracted b-lactamase (29).
Mueller-Hinton broth (Difco, Amsterdam, The Netherlands) supplemented with
Ca21 (25 mg/liter) and Mg21 (12.5 mg/liter) (MHBs) was used in all experi-
ments. All bacterial samples were plated on Tryptone soy agar (TSA; Oxoid,
Basingstoke, Hampshire, England).
Antibiotics. Tobramycin was obtained from Eli Lilly and Company (Nieu-
wegein, The Netherlands) and ceftazidime was obtained from Glaxo (Zeist, The
Netherlands). Stock solutions were prepared according to the guidelines of the
National Committee for Clinical Laboratory Standards (24).
FIC indices. Fractional inhibitory concentration indices (FICi) were deter-
mined by a modified dilution checkerboard macrotitration technique (12) with
synergism defined as a FICi of #0.8 (13). When two-fold dilution series were
used synergism was defined as a FICi #0.5 (28). FICs and FICi were calculated
in the usual way (2, 7).
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Time-kill curves. Time-kill curves were performed with tobramycin and cefta-
zidime alone and in combination at concentrations of 0.125, 0.25, 0.5, 1, and 2
times the MIC in shaking tubes containing 10 ml. For each experiment a fresh
overnight culture was made in MHBs at 378C, and then diluted in prewarmed
MHBs and shaken for 2 h, resulting in a starting inoculum of approximately 5 3
105 CFU/ml. Samples of this logarithmic culture were diluted with prewarmed
antibiotic solutions containing two times the final antibiotic concentration, or for
the control pure MHBs. Samples were taken at 0, 1, 2, 4, 6, and 24 h of
incubation. The numbers of CFU/ml were determined after making appropriate
dilutions in cold saline, and 0.1 ml was plated on TSA plates, and incubated
overnight at 378C. All time-kill curves were performed in duplicate. Synergism in
time-kill methods is defined as a decrease $2 log10 CFU/ml in the combination
regimen compared to the best monotherapy regimen (28). The area under the
bacterial killing curve (AUKC0-24h) was calculated by using the trapezoidal rule
on logarithmically transformed observed data points.
In vitro pharmacokinetic model. The model used was described in detail
previously (21). Briefly, a two-compartment model consisting of one central
compartment and three peripheral compartments (disposable dialyzer units
[ST23; Baxter, Utrecht, The Netherlands]) was used to expose the bacteria in the
peripheral compartments to changing antibiotic concentrations, mimicking hu-
man pharmacokinetics. At t 5 0 h the peripheral compartments were inoculated
with a logarithmic culture of P. aeruginosa CF 133 of approximately 5 3 105
CFU/ml, prepared separately for each compartment as described for the time-
kill method. Control growth curves of P. aeruginosa CF 133 in the in vitro model
were determined the same way only without adding antibiotics.
Dosing regimens. The following dosing regimens were tested over 24 h: to-
bramycin monotherapy q8h daily and once daily, ceftazidime monotherapy q8h
daily, combination therapy of tobramycin q8h and ceftazidime q8h at indicated
time intervals, t5 0, 8, and 16 h and t5 20 min, 8 h 20 min, and 16 h 20 min (i.e.,
simultaneous administration), or t 5 0, 8, and 16 h and t 5 4, 12, and 20 h (i.e.,
non-simultaneous administration), and finally combination therapy of tobramy-
cin once daily and ceftazidime q8h daily. The antibiotics were infused over 20
minutes, and the peak concentration was determined at 10 minutes after the
infusion (t 5 30 min.). In the q8h daily regimen the dose was chosen to obtain
a peak concentration identical to the MIC for the strain (i.e., 16 mg/liter for
tobramycin and 64 mg/liter for ceftazidime). For the once-daily tobramycin
regimen the dose was chosen to obtain a peak concentration of 32 mg/liter (2 3
MIC). The half life (t1/2) for both tobramycin and ceftazidime was adjusted to 2
hours. One-milliliter samples were taken from t5 0 h, every hour, and at t5 0.5,
4.5, 8.5, 12.5, 16.5, and 20.5 h. The samples were immediately washed (twice)
with sterile cold saline and 0.1 ml was plated on TSA plates (limit of detection 5
10 CFU/ml). Samples were assayed for tobramycin by fluorescence polarization
immunoassay using TDxFLx (Abbott Diagnostic Division, Amstelveen, The
Netherlands) and for ceftazidime by high-performance liquid chromatography
(HPLC) as described earlier (23). The lower limit of sensitivity of the assay was
0.5 mg/liter. The between-day between-sample variation was less than 7%. Con-
trol runs were performed regularly.
MICs. MICs for the strains isolated at t 5 0, 8, 16, and 24 h were determined
using a standard agar dilution method (24), to determine development of resis-
tance during the experiment. To detect more resistant mutants in the starting
inoculum, a fresh logarithmic culture of P. aeruginosa CF 133 was plated on
ISO-agar plates containing tobramycin or ceftazidime at a concentration of 8, 16,
32, 64, 128, or 256 mg/liter and 32, 64, 128, 256, 512 or 1,024 mg/liter, respec-
tively.
Initial bactericidal effect. The initial killing effect of a regimen was expressed
as changes in log10 CFU/ml at one fixed time point during an experiment, or as
the time needed to reduce the inoculum to 103 CFU/ml (1).
Statistical analysis. Peak and trough concentrations, half-life of the antibiotics
during the different experiments and the time kill curves (i.e., the difference
between the log10 CFU/ml at t 5 0 h and t 5 8, and t 5 0 and 24 h, the time to
a 103 CFU/ml reduction of the inoculum) were compared by using a two-way
analysis of variance (ANOVA) and Tukey’s test for multiple comparison of
significance. For analysis of the AUKC, time kill curves were compared with each
other using a two-way analysis of variance (ANOVA) for repeated measure-
ments. Monotherapy was tested against combination therapy, combination ther-
apy regimens were tested against each other, and single-dose tobramycin was
tested against multiple-dose tobramycin. The Instat 2 computer package (9) was
used for all statistical analysis. A P value of 0.05 two-tailed was considered
significant.
RESULTS
Mechanism of resistance. The P. aeruginosa CF 133 pro-
duced aminoglycoside-modifying enzymes, which were identi-
fied as AAC (69) II and APH (39), and produced a b-lactamase
which was identified as a stably depressed chromosomal en-
coded class I b-lactamase (4).
FIC indices. The FICi of P. aeruginosa CF 133 for tobramy-
cin and ceftazidime, determined using a two-fold dilution
method for the checkerboard titration, was 0.55, indicating
indifference. However, if the modified macrotitration tech-
nique was used (12), the FICi was 0.37, indicating synergism
between tobramycin and ceftazidime for this strain (13).
Time-kill curves. Numbers of log10 CFU/ml of single agent
exposure and combination agent exposure at different antibi-
otic concentrations at the end-point (t 5 24 h) are shown in
Fig. 1. Combination therapy showed a significant increase in
killing over monotherapy if the concentrations were $one-half
MIC, but this effect was not large enough to label it synergism
according to the definition.
The AUKC0-24h calculated for all killing curves are shown in
Table 1. For each concentration the AUKC0-24h of the best
monotherapy regimen was compared to the AUKC0-24h com-
bination therapy. All combinations at concentrations #one
MIC showed a significantly smaller AUKC0-24h than mono-
therapy (Table 1). At 2 3 MIC no significant difference be-
tween tobramycin monotherapy and combination therapy was
found, probably due to the pronounced killing of tobramycin,
when it is used above the MIC as in this experiment.
Pharmacokinetic data. The peak and trough concentrations
of tobramycin and ceftazidime and the t1/2 obtained in the in
vitro model during the different dosing regimens showed no
significant differences. The peak concentrations were 13.8 6
1.2 mg/liter, 33.7 6 2.0 mg/liter, and 53.1 6 5.3 mg/liter, and
the trough concentrations were 1.7 6 0.5 mg/liter, 0.1 6 0.1
FIG. 1. Difference in bactericidal effect after 24 h exposure to tobramycin
(u) or ceftazidime (2) alone and in combination (n) at a concentra-
tion range of 2 3 MIC to 1/8 3 MIC. Control growth curve (uzzz ). Data are
means 6 SD of two experiments of the CFU/ml present at 24 h.
TABLE 1. Bactericidal activity of tobramycin and ceftazidime given
alone or in combination towards a tobramycin and ceftazidime
resistant P. aeruginosa, expressed as the AUKC0-24h (6 SD)
determined in conventional time-kill experiments
Antibiotic
concentration
AUKC0-24h
P valueaTobramycin
monotherapy
Ceftazidime
monotherapy
Combination
therapy
2 3 MIC 93 6 5 102 6 2 77 6 7 0.131
1 3 MIC 126 6 4 122 6 3 89 6 3 0.008
1/2 3 MIC 148 6 1 141 6 1 95 6 1 0.001
1/4 3 MIC 159 6 5 149 6 4 123 6 1 0.012
1/8 3 MIC 173 6 4 156 6 1 140 6 1 0.001
a P value obtained by comparing the best single agent exposure to the com-
bination agent exposure.
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mg/liter, and 5.1 6 1.1 mg/liter for tobramycin (q8h), tobra-
mycin (q24h), and ceftazidime (q8h), respectively. The t1/2 was
2.3 6 0.2 h, which is slightly but not significantly higher than
the intended half-life. The half-lives for both drugs were not
significantly different.
Growth curve and monotherapy. Monotherapy with tobra-
mycin (q8h and q24h) and ceftazidime (q8h) showed an initial
decrease in CFU/ml of this resistant strain to approximately
104 CFU/ml during the first hours of treatment, followed by a
bacterial regrowth (Fig. 2a). There was no significant differ-
ence between the effect of the three monotherapy dosing reg-
imens determined by comparing the Dlog10 CFU/ml at t 5 8
and 24 h (Table 2). All monotherapy regimens showed a slight
growth retardation compared to the control growth curve.
FIG. 2. Growth and killing curves of P. aeruginosa CF 133 in an in vitro pharmacokinetic model during monotherapy with tobramycin q8h (——), q24h (——,
and ceftazidime q8h (—V—) (a) and during combination therapy regimens tobramycin (q8h) at t 5 0 h and ceftazidime (q8h) at t 5 20 min (—M—), and vice versa
(—v—) (b), tobramycin (q8h) at t 5 0 h and ceftazidime (q8h) at t 5 4 h (——), and vice versa (——) (c), and tobramycin (q24h) at t 5 0 h and ceftazidime (q8h)
at t 5 20 min (—»—, and vice versa (—e—) (d). Data are geometric means 6 SD of two separate experiments, performed in triplicate. —f— in all panels denotes
the control growth curve of the test strain in absence of antibiotics.
TABLE 2. Bactericidal activity of tobramycin and ceftazidime given alone or in combination for a tobramycin and ceftazidime
resistant strain of P. aeruginosa, in an in vitro pharmacokinetic model
Dosing regimen
Dlog10 CFU/mla Time to reduce the inoculum
(5 3 105 CFU/ml) to
,103 CFU/ml (h)t 5 8 h t 5 24 h
Tobramycin q8h 21.2 6 0.1 1.4 6 0.1 `
Tobramycin q24h 21.1 6 0.1 2.3 6 0.4 `
Ceftazidime q8h 20.8 6 0.1 1.4 6 0.3 `
Tobramycin (q8h) at t 5 0 h/ceftazidime (q8h) at t 5 20 min 22.1 6 0.1 22.9 6 0.8b 9.6 6 0.4
Ceftazidime (q8h) at t 5 0 h/tobramycin (q8h) at t 5 20 min 22.7 6 0.5 21.3 6 1.0b 4.8 6 0.2
Tobramycin (q8h) at t 5 0 h/ceftazidime (q8h) at t 5 4 h 22.1 6 0.1 21.2 6 0.3b 8.3 6 0.5
Ceftazidime (q8h) at t 5 0 h/tobramycin (q8h) at t 5 4 h 22.6 6 0.2 22.6 6 0.3b 9.9 6 4.7
Tobramycin (q24h) at t 5 0 h/ceftazidime (q8h) at t 5 20 min 23.9 6 0.8b 22.6 6 1.3b 2.2 6 0.6
Tobramycin (q24h) at t 5 20 min/ceftazidime (q8h) at t 5 0 h 23.3 6 0.3b 22.0 6 0.3b 1.7 6 0.1
a Data are means 6 SD of two separate experiments, performed in triplicate.
b Decrease in Dlog10 CFU/ml .2 log10, compared to the best monotherapy regimen.
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Combination therapy. All four combination therapies in-
cluding q8h tobramycin showed an initial killing during the first
five hours of treatment, followed by a stabilization of the col-
ony counts around 103 CFU/ml (Fig. 2b and c). By comparing
the Dlog10 CFU/ml at t 5 8 h and 24 h, no differences were
found among all combination therapy regimens. However, the
Dlog10 CFU/ml of all combination therapy regimens were sig-
nificantly different from all monotherapy regimens.
Combination therapy regimens, including q24h tobramycin,
showed a pronounced killing during the first three hours of
treatment. When tobramycin was given before ceftazidime the
colony counts stabilized around 102 to 103 CFU/ml; however, if
ceftazidime was given as the first agent a slight bacterial re-
growth was seen to 103 to 104 CFU/ml (Fig. 2d). This differ-
ence was not significant at t 5 24 h (P 5 0.47, Table 2).
Calculating the time needed to reduce the inoculum to 103
CFU/ml (Table 2) as a parameter for the initial killing effect, as
described by Barclay et al. (1), demonstrated that the combi-
nation therapy regimens with tobramycin q24h had a signifi-
cantly faster initial killing compared to all other combination
therapy regimens (0.001 , P , 0.01), except for the q8h
combination therapy regimen with ceftazidime given at t 5 0 h
and tobramycin at t 5 20 min.
Synergism. Synergism was shown by a decrease $2 log10
CFU/ml compared to the best monotherapy regimen at t5 8 h
only for the tobramycin q24h combination therapy regimens,
and at t5 24 h for all combination therapy regimens (Table 2).
Synergism was also determined by calculation of the area
under the bacterial killing curve (AUKC). An AUKC (0 to 8 h,
0 to 16 h, and 0 to 24 h) was calculated for all dosing regimens.
If the AUKC was significantly smaller for a combination ther-
apy compared to the best monotherapy regimen, it was con-
sidered as synergism. The cumulative AUKC at t 5 8, 16, and
24 h showed that at t 5 8 h both combination therapies using
tobramycin once daily gave a significant smaller AUKC than
all other regimens (P, 0.001) (Fig. 3). At t5 16 h and t5 24 h
all combination therapy regimens show a significant smaller
AUKC than all monotherapy regimens, with one combination
therapy regimen being significantly better than all other regi-
mens (tobramycin once daily at t 5 0 h, and ceftazidime thrice
daily at t 5 20 min, 8 h 20 min, and 16 h 20 min (0.0001 , P ,
0.01)).
Emergence of resistance. The MICs of the bacteria isolated
during combination therapy regimens at t 5 8, 16, and 24 h
increased about 4 times for tobramycin, but remained 64 mg/
liter for ceftazidime. During monotherapy the MICs for the
bacteria increased about four times for tobramycin and cefta-
zidime. No statistical difference in MIC rise was found between
the dosing regimens. No resistant mutants could be detected in
the logarithmic culture of the starting inoculum as used in all
experiments.
DISCUSSION
The main purpose of this study was to determine whether a
combination of tobramycin and ceftazidime, with peak concen-
trations in the range of the MIC and at declining concentra-
tions over time, resulted in synergism. This means that the
concentration was below the MIC for both agents during the
complete experiment. When determining synergism, at least
FIG. 3. Bactericidal effect of tobramycin or ceftazidime alone or in combination expressed as the cumulative area under the bacterial killing curve (AUKC). Lines
represent tobramycin q8h alone (——), tobramycin q24h alone (——), and ceftazidime q8h alone (—f—), combination therapies tobramycin (q8h) at t 5 0 h and
ceftazidime (q8h) at t 5 20 min (—»—), and vice versa (—M—), tobramycin (q8h) at t 5 0 h and ceftazidime (q8h) at t 5 4 h (—l—), and vice versa (——),
tobramycin (q24h) at t 5 0 h and ceftazidime (q8h) at t 5 20 min (——), and vice versa (—e—). Data are means 6 SD of two separate experiments performed in
triplicate.
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one of the drugs should have a concentration which does not
affect the bacterial growth (8). The only experiment where the
peak concentration exceeded the MIC was when tobramycin
was given once daily. This protocol thus provided a good cir-
cumstance to demonstrate synergism. If killing was observed
this can only be explained as being due to synergism, because
at concentrations below the MIC, growth can be expected
when only monotherapy is given. The results indicate that
synergism is present at 24 h for all tested combination regi-
mens of tobramycin and ceftazidime, as shown by a decrease
$2 log10 CFU/ml compared to all monotherapy regimens (Ta-
ble 2). While growth occurred during all monotherapy exper-
iments (Fig. 2a), the final CFU/ml in combination therapy
always was below the starting inoculum.
The choice of combinations of antimicrobial agents in ther-
apy is often based on the MIC, and sometimes on a possible
synergism demonstrated by determination of the FICi in a
standard checkerboard titration, or by time kill curves. The
FICi of the Pseudomonas strain used in the experiments was
0.55 when using a two-fold dilution checkerboard titration
method, indicating indifference between tobramycin and cefta-
zidime. However when using the modified dilution checker-
board titration (12), the FICi was 0.37, indicating a high degree
of synergism between tobramycin and ceftazidime. This con-
firms the observations of Horrevorts et al. (12, 13) that the
FICi determined by a modified checkerboard titration is a
more sensitive technique for detecting synergism, due to the
use of smaller intervals between the dilution steps. Unfortu-
nately, studies show discordance between the results of check-
erboard titrations and time-kill curve methods (25), between
FICi and in vitro model studies (20, 32), and between FICi and
clinical outcome (5, 26). Possibly, the simulation of declining
antibiotic concentrations as can be produced in in vitro phar-
macokinetic models is a better method to study synergism.
Observations from these models may correlate better with
clinical outcome since they are a better simulation of situations
in patients.
In time kill curves, synergism is always determined at one
time-point only (usually t5 24 h), while synergism between the
antibiotics is present during the complete experiment, and thus
at each time-point. To take these dynamics into account more
time points should be taken for the calculation of synergism.
When using the AUKC0-24h as a parameter for the killing
effect, all time-points during the experiments are used. Thus,
the AUKC0-24h may be a better parameter of synergism. This
method can be used for both conventional time-kill curves and
for time-kill curves determined in in vitro models. By defining
synergism as a significantly smaller AUKC0-24h of the combi-
nation therapy compared to the best monotherapy regimen, all
combination therapy regimens showed synergism. However, by
using the significant differences in AUKC0-24h only, one does
not differentiate between synergism and additivity (or indiffer-
ence). But it is questionable if such differentiation is clinically
relevant. When combination therapy results in a significantly
increased killing compared to monotherapy, combination ther-
apy could be justified, even if there is only additivity. In clinical
practice knowledge about killing during the complete time
period of treatment may well be more important than just at a
single time point (t 5 24 h).
The significantly faster initial killing as seen in the combi-
nation regimens with tobramycin once daily can be explained
by a fast initial killing of the bacteria susceptible to tobramycin
since in this case the concentration remained above the MIC
for about two hours. But this fast initial killing cannot be fully
explained by this high peak concentration, since it was not seen
in the tobramycin once daily monotherapy regimen. Thus this
fast initial killing has to be at least in part a result of the
synergism of the combined agents.
During all combination therapy regimens only emergence of
resistance for tobramycin was shown. The MICs of ceftazidime
did not change during combination therapy. During mono-
therapy however, the MICs of both tobramycin and ceftazi-
dime increased about four times. In the starting inoculum no
resistant mutants could be detected by plating on an antibiotic
containing agar. This indicates that combination therapy may
prevent emergence of resistance.
Barclay et al. (1) described a study investigating simulta-
neous and nonsimultaneous infusions of gentamicin and cefta-
zidime against three susceptible P. aeruginosa strains in an in
vitro pharmacokinetic dilution model. Several time points were
tested for infusion; however, only one injection of the antibi-
otics was used in those experiments. They concluded that the
nonsimultaneous administration produced greater overall kill-
ing and delay in bacterial regrowth. Ko¨nig et al. (18) investi-
gated the dosing regimen of gentamicin and ampicillin against
E. coli, and later the same group published the combination of
gentamicin and ticarcillin against P. aeruginosa (10). Both stud-
ies showed a greater overall bacterial killing and delay in bac-
terial regrowth in using nonsimultaneous administration given
4 hours apart. Our study could, however, not confirm this,
possibly due to the fact that we used a resistant strain.
Some reservations should be made concerning the fact that
only one strain was tested with one specific mechanism of
resistance. It may be possible that the conclusions based on the
data for the tested strain will be different for strains with other
mechanisms of resistance. At present, this limits the ability to
generalize the conclusions to other strains.
In conclusion, this study indicates that infections due to a
resistant Pseudomonas strain, such as frequently occur in pa-
tients with cystic fibrosis, possibly can be treated with a syner-
gistic combination of the antibiotics to each of which the strain
is resistant. With b-lactam-plus-aminoglycoside combination,
the best effect is possibly produced if once daily doses of the
aminoglycoside are combined with multiple daily doses of the
b-lactam, since this may result in the fastest initial killing rates
and in the smallest AUKC0-24h.
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